Guidance for Industry
Orally Disintegrating Tablets

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Frank O. Holcombe, Jr., Ph.D., 240-276-9310.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

April 2007
Chemistry

Dr. Falk Pharma Ex. 1007
IPR Petition - USP 10,632,069

Guidance for Industry
Orally Disintegrating Tablets

Additional copies are available from:
Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
http://www.fda.gov/cder/guidance/index.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

April 2007
Chemistry

5909dft.doc
3/22/07

TABLE OF CONTENTS

I. INTRODUCTION 1

II. BACKGROUND 1

III. DISCUSSION 2

IV. DISINTEGRATION TESTING 3

Guidance for Industry[1]
Orally Disintegrating Tablets

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance provides pharmaceutical manufacturers of new and generic drug products with an Agency perspective on the definition of an *orally disintegrating tablet* (ODT), which is a different dosage form than, for example, a chewable tablet or a tablet that should be swallowed whole with liquid, and also provides recommendations to applicants who would like to designate proposed products as ODTs.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

In an effort to develop drug products that are more convenient to use and to address potential issues of patient compliance for certain product indications and patient populations, pharmaceutical manufacturers have developed products that can be ingested simply by placing them on the tongue. The products are designed to disintegrate or dissolve rapidly on contact with saliva, thus eliminating the need for chewing the tablet, swallowing an intact tablet, or taking the tablet with water. This mode of administration was initially expected to be beneficial to pediatric and geriatric patients, to people with conditions related to impaired swallowing, and for treatment of patients when compliance may be difficult (e.g., for psychiatric disorders).

[1] This guidance was prepared by the Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

After the Agency received and reviewed applications for the initial products, the CDER Nomenclature Standards Committee developed the following definition for an orally disintegrating tablet (ODT) as a new dosage form in 1998:

> *A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.*[2]

Characteristics that were exhibited by the initial products included low tablet weight, small size, highly soluble components, and rapid disintegration. Such characteristics supported the intended uses of these products.

However, as firms started developing additional products using different technology and formulations, many of these later products exhibited wide variation in product characteristics from the initial products. Because this shift in product characteristics can affect suitability for particular uses, the Agency developed this guidance for industry.

III. DISCUSSION

As briefly discussed in Section II, an ODT has previously been distinguished as a separate dosage form because of the specific, intended performance characteristics of such products, which are rapid oral disintegration in saliva with no need for chewing or drinking liquids to ingest these products. These characteristics, which are an aid to patient use and compliance, are the primary characteristics that constitute the basis for classifying a product as an ODT.

The recommendations in this guidance are based on the intention of the original definition and on Agency experience with new drug applications (NDAs) and abbreviated new drug applications (ANDAs) submitted for this dosage form. To determine what the Agency's experience has been, we surveyed applications for products submitted to the Agency, completed a literature review, and collected information from laboratory studies that showed although disintegration times ranged from a few seconds to longer than a minute, a large majority of these products have in-vitro disintegration times of approximately 30 seconds or less. These products represented different manufacturing technologies, a variety of tablet sizes and weights, and various disintegration strategies demonstrating that relatively rapid disintegration is readily achievable across a variety of products.

Products labeled as ODTs should match the characteristics for this dosage form (rapid disintegration in saliva without need for chewing or drinking liquids). Based on the original product rationale and Agency experience, we recommend that, in addition to the original definition, ODTs be considered solid oral preparations that disintegrate rapidly in the oral cavity, with an in vitro disintegration time of approximately 30 seconds or less, when based on the United States Pharmacopeia (USP) disintegration test method or alternative (see section IV).

[2] CDER Data Standards Manual

Although the value of 30 seconds is given as a desired result, it is not intended to represent an arbitrary distinction between an ODT and some other tablet form. It is instead representative of a general time period associated with drug products that have been found to have performance characteristics appropriate for a disintegrating tablet meant to be taken without chewing or liquids.

We recommend that as a primary consideration when developing this type of product you use the defining characteristics for this dosage form designation (rapid disintegration in saliva without need for chewing or liquids). Products should be developed to match these characteristics, rather than labeling a tablet as an ODT because it would eventually disintegrate when placed in the mouth. For example, tablets that take longer than 30 seconds to disintegrate or are dosed with liquids may be more appropriately considered to be chewable or oral tablets.

Additional parameters for consideration during product development are tablet size, weight, component solubility, and the effect these factors have on the intended use of the product. While tablet size or weight is not explicitly included in the definition, you should consider the effect large tablets have on patient safety and compliance. We recommend that the weight of the tablet not exceed 500 mg. If it does, the extent of component solubility (e.g., tablet residue, need for liquids) can influence the acceptability of a large tablet being labeled as an ODT.

IV. DISINTEGRATION TESTING

Part of the process of determining if a product is an ODT involves testing a product to see how long it takes to disintegrate. Determination of disintegration time appears to be method dependent. There are many methods—some more discriminating than others. To provide both a standard for and consistency in disintegration testing, we recommend that applicants use the USP method for disintegration testing.[3] However, other methods that can be correlated with or are demonstrated to provide results equivalent to the USP method can also be used and submitted to determine disintegration time.

[3] *USP 29, <701> Disintegration*, pp 2670-2672.